SANTA CLARA, Calif., Aug. 9 /PRNewswire/ --
Applied Imaging Corp. (Nasdaq: AICX) announced that it has received a U.S.
patent for the detection of cells and other objects of interest through the
analysis of multiple microscopic images. This patent further protects
techniques developed by the Company to detect and analyze targeted cells, such
as cancer cells, using brightfield and fluorescence microscopy.
The use of this patented technology in the company's MDS(TM) system allows
for the analysis of cellular proteins and genes within an individual cell or
in a tissue section taken from a tumor. Protein and gene expression profiles
are increasingly being used to guide the selection of appropriate therapies.
For example, promising new therapeutics, such as Herceptin(R) and Gleevec(R),
are being targeted to patient populations selected using combinations of such
test results.
Applied Imaging CEO Carl Hull stated, "We are very pleased to have
received our fourth U.S. patent in the last 12 months protecting technologies
that we believe are central to determining the results of advanced cellular
assays. Many of these innovative techniques are incorporated in our MDS(TM)
automated imaging system and allow the system to perform rapid,
multiparametric analyses of cancer cells to detect and more precisely
characterize the disease."
Applied Imaging's MDS(TM) System is an advanced scanning microscopy system
that detects targeted cancer cells in concentrations as low as one cell among
one million other cells. Once detected, the MDS(TM) utilizes proprietary
fluorescence analysis software for the genetic characterization of these
cells.
Patent Information
Patent No. 6,259,807 entitled "Identification of Objects of Interest Using
Multiple Illumination Schemes and Finding Overlap of Features in Corresponding
Multiple Images" was issued on July 10, 2001.
About Applied Imaging
Applied Imaging Corp., based in Santa Clara, California, is the leading
supplier of automated imaging systems utilized in genetics and pathology
laboratories for the analysis of chromosomes in cancer and prenatal disorders.
The Company has installed over 2000 imaging systems in 1000 laboratories in
more than 35 countries. Applied Imaging markets a range of clinical and
research imaging systems for fluorescence and brightfield microscopy
applications, including the Company's MDS(TM), CytoVision(R), PowerGene(R) and
QUIPS(R) product lines.
NOTE: Herceptin(R) is a registered trademark of Genentech, Inc.
Gleevec(R) is a registered trademark of Novartis.
This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, regarding the competitive
advantage that results from the issuance of the patent referenced herein.
Forward looking statements address matters that are subject to a number of
risks and uncertainties, including the Company's ability to compete
effectively in the future with various other companies, some of which have
greater resources than does the Company and other such factors as set forth in
the Company's form 10-K for the year ended December 31, 2000 as filed with the
Securities and Exchange Commission.
For additional information please contact Applied Imaging, the Financial
Relations Board or visit the Company's web site at http://www.aicorp.com .
SOURCE Applied Imaging Corp.
 back to top
Related links:
http://www.aicorp.com
CONTACT:
Barry Hotchkies, CFO of Applied Imaging
Corp., +1-408-562-0250; or investors, media, Liz Saghi, or
general, Pam Roberts, both of Financial Relations Board,
+1-415-986-1591, for Applied Imaging Corp.
|
